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Abstract
An optogenetic Bax has been designed that facilitates light-induced apoptosis. We demonstrate 
that mitochondrial recruitment of a genetically encoded light-responsive Bax results in the release 
of mitochondrial proteins, downstream caspase 3 cleavage, changes in cellular morphology, and 
ultimately cell death. Mutagenesis of a key phosphorylatable residue or modification of the C-
terminus mitigates background levels (dark) of apoptosis due to Bax overexpression. The 
mechanism of optogenetic Bax-mediated apoptosis was explored using a series of small molecules 
known to interfere with various steps in programmed cell death. Optogenetic Bax appears to form 
a mitochondrial apoptosis-induced channel analogous to that of endogenous Bax.
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Light has been used to control the biochemistry of cells, manipulate the behavior of 
organisms, and treat diseases such as cancer.[1] Recently, the application of genetically-
encoded light responsive proteins for controlling the biochemistry, and therefore the 
behavior, of cells and organisms has elicited widespread attention.[2] Indeed, a database 
search revealed that the term “optogenetics” is found in well over 800 funded NIH grants 
(NIH RePorter) and in more than 200 reviews (PubMed). However, the majority of studies to 
date have employed light-responsive proteins appropriated from microorganisms (e.g. ion 
channels) that have been applied to the arena of neuroscience.[3] By contrast, relatively few 
light-activatable analogs of endogenous mammalian proteins have been successfully 
engineered.[4] Indeed, strategies for the design of optogenetic proteins have been described 
as “still in the development stage”.[5] With this challenge in mind, we report the design, 
construction, and application of a genetically encoded inducer of programmed cell death 
(apoptosis).
Apoptosis is a highly regulated self-contained response to stress-inducing environmental 
challenges. This dynamic process is modulated by a diverse array of proteins that, upon 
malfunction, contribute to diseases that range from cancer to neurological disorders. 
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Optogenetic analogs of apoptotic protein participants could potentially be used to 
exogenously modulate (and thereby interrogate) life/death decisions with exquisite 
biochemical, spatial, and temporal precision. For example pro- and anti-apoptotic members 
of the Bcl-2 family of proteins work in concert to control outer mitochondrial membrane 
(OMM) permeabilization, a critical event during apoptosis.[6] In addition, a large number of 
non-Bcl-2 proteins are recruited to the OMM, and assist the Bcl-2 proteins in the decision 
making process that governs cell fate.[7] We describe herein the design and behavior of an 
optogenetic Bax. Bax, a key effector of apoptosis, translocates from the cytosol to the OMM 
in response to apoptotic-inducing insults.[8] Once OMM associated, Bax oligomerizes and 
subsequently participates in the formation of the mitochondrial apoptosis-induced channel 
(MAC) through which cytochrome c is released into the cytosol. Key elements of our 
optogenetic Bax design strategy include (a) the application of light to induce a Bax 
concentration jump at the OMM surface to promote Bax oligomerization and (b) the 
introduction of mutations to reduce background (i.e. dark) activity of Bax. “Dark activity” is 
a common problem that has bedeviled the acquisition of well-behaved optogenetic 
species.[5] We demonstrate herein the light-triggered recruitment of several Bax constructs to 
mitochondria, the permeabilization of the OMM via release of Smac1 and subsequent 
cleavage of caspase 3, and that the mechanism of optogenetic Bax-driven apoptosis appears 
to recapitulate that of the endogenous protein.
We built upon previous work from our lab, which employed a photo-heterodimerizer 
system,[9] to engineer Bax constructs that are recruited to mitochondria upon illumination 
(Scheme 1). In brief, Cry2 (derived from a flavin-containing cryptochrome photoreceptor) 
undergoes a rapid conformational change upon brief exposure to 488 nm.[10] In the light-
activated state, Cry2 binds to a protein partner (Cib) to form a transient Cry2-Cib 
complex.[10] For our initial studies, we prepared a Tom20-Cib-GFP construct, where Tom20 
is a fragment of a protein that is anchored to the surface of the OMM.[11] This places the Cib 
component at the intracellular site that endogenous Bax associates with in response to 
apoptotic-inducing environmental events.[11] We first examined the light-triggered migration 
of a Cry2-mCh (mCherry) construct from the cytoplasm to the OMM by simultaneously 
expressing it along with Tom20-Cib-GFP in multiple cell lines (Cos7, HeLa, MtLn3; Fig. 1; 
Supporting Fig. 1, Supporting Movies 1 & 2). A single 10 ms pulse proved to be sufficient to 
alter the spatial distribution of Cry2-mCh from diffuse cytoplasmic to mitochondrial within 
30 s. The dark half-life of the mitochondrial localized post-illuminated Cry2-Cib construct is 
140 s.
In order to address the issue of dark activity, which typically compromises the design and 
acquisition of optogenetic proteins, we prepared variants of Bax that preclude association 
with mitochondria. In particular, we focused our attention on the C-terminus of the protein 
as well as the S184 residue, both of which play key roles in regulating the cytosolic/
mitochondrial distribution of Bax. A free C-terminus is known to be essential for Bax 
mitochondrial migration in response to an apoptotic stimulus.[12] In addition, the 
phosphorylation status of S184 is known to control Bax localization, where phospho184 Bax 
is cytoplasmic and the dephospho-form is mitochondrial.[13] With these features in mind, we 
prepared the following: (1) Free C-terminus Bax constructs Cry2-mCh-BaxWT, the S184E 
phospho-mimetic Cry2-mCh-BaxS184E, and the nonphosphorylatable S184V Cry2-mCh-
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BaxS184V; (2) Substituted C-terminus constructs BaxWT-Cry2-mCh, BaxS184E-Cry2-mCh, 
and BaxS184V-Cry2-mCh (Table 1, Supporting Fig. 2). The phospho-mimetic mutant 
Ser184Glu is reported to generate a cytosolic Bax, whereas introduction of a hydrophobic 
residue (Ser184Val) induces constitutive mitochondrial localization of Bax.[13] The 
approximate predicted masses of all the constructs were confirmed via western blot analysis 
(Supporting Fig. 2).
We tested the free C-terminus constructs Cry2-mCh-BaxWT, Cry2-mCh-BaxS184E, Cry2-
mCh-BaxS184V in the dark. All behaved as predicted where the S184E is cytoplasmic and 
the S184V is mitochondrial, with numerous peri-mitochondrial speckles. The latter is 
consistent with the formation of pre-apoptotic, mitochondrially associated Bax clusters[1] 
(Supporting Fig. 3). The Cry2-mCh-BaxWT is both mitochondrial and cytoplasmic, 
consistent with the fact that WT Bax is known to exist in equilibrium between mitochondria 
and cytosol.[14] We also examined the C-substituted Bax constructs (Bax-Cry2-mCh) in the 
dark and found that all three are cytoplasmic. This demonstrates the profound effect of Bax 
C-substitution, which even overwhelms the S184V mutation that ordinarily would drive Bax 
to the mitochondria.[13] We subsequently analyzed the response of these Bax constructs to 
treatment with staurosporine (STS), a broad spectrum protein kinase inhibitor that induces 
apoptosis. Within 2 h, constructs with Bax at the C-terminus (Cry2-mCh-Bax) are recruited 
to the mitochondria, whereas the corresponding Bax-Cry2-mCh proteins remain cytoplasmic 
(Supporting Fig. 4). The inability of the Bax-Cry2-mCh constructs to undergo STS-induced 
recruitment to the mitochondria demonstrates that Bax, with an exposed free C-terminus, is 
absolutely essential for mitochondrial association. It further suggests that blocking the C-
terminal domain may be an effective way of limiting background cell death associated with 
Bax overexpression.
We subsequently examined the light initiated recruitment of both Cry2-mCh-BaxS184E and 
BaxS184E-Cry2-mCh constructs to mitochondria in HeLa cells. We observed rapid cell 
collapse upon mitochondrial recruitment of Cry2-mCh-BaxS184E over a 1 h time course of 
illumination (10 ms every 2 min) and imaging (Fig. 2). In an analogous fashion, cells 
harboring BaxS184E-Cry2-mCh collapse and die upon illumination. However, this occurs 
over a significantly longer time period (2 – 3 h) than that required for Cry2-mCh-BaxS184E 
(Supporting Movie 2). We also performed the following control experiments: (1) 
Mitochondrial recruitment of the construct lacking Bax, namely Cry2-mCh, under identical 
conditions does not result in a loss in cell viability (Supporting Movie 2/Fig. 2). In addition 
(2), we tested the effect of recruiting Cry2-mCh-BaxS184E to the plasma membrane using 
Cib-GFP-CAAX, where CAAX serves as a plasma membrane localization motif. Sustained 
recruitment of Cry2-mCh-BaxS184E to the plasma membrane does not result in cell collapse, 
indicating that the activity of optogenetic Bax is specific to the OMM (Supporting Movie 3/
Supporting Fig. 5).
We also examined the effect of light-induced mitochondrial recruitment of Bax on long term 
cell viability (24, 48 h) using a trypan blue exclusion assay (Supporting Figs. 6 – 7).[15] 
Since this particular experiment required a relatively large cell population, we employed an 
in-house built LED array for illumination purposes (as opposed to illumination under the 
microscope). The photon flux produced by our LED array (6.9 ± 0.4 µmol m-2 s-1) is 
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significantly less than that received by cells under the microscope (296 ± 1 µmol m−2 s−1), 
and thus we employed a more aggressive illumination protocol (2 s every 2 min for 2 h). 48 
h after light exposure, >60% of the Cry2-mCh-BaxS184E cells had detached from the plate 
and nearly half of the remaining adherent cells incorporated trypan blue (and were therefore 
non-viable). By contrast, only 11% of the cells transfected with the Cry2-mCh control and 
illuminated were non-viable and only 8% of the cells in the non-transfected control were 
non-viable.
We also explored the minimum number of light pulses required to promote mitochondrial 
association. We found that, while a single 100 ms pulse is not sufficient to induce apoptosis, 
differences in behavior between the various constructs are nonetheless apparent even under 
these conditions (Supporting Fig. 8). Specifically, the mitochondrial residence time (half-
life) of the Cry2-mCh-Bax fusions is significantly longer (200 ± 10 s) than their Bax-Cry2-
mCh counterparts (130 ± 10 s) (Table 1, Supporting Fig. 8). Subsequent studies using a 
series of five 10 ms pulses, spaced 5 min apart, revealed that Cry2-mCh-BaxS184E remains 
associated with the mitochondria, even 30 min after the final 10 ms pulse (Supporting Fig. 
9). By contrast, the BaxS184E-Cry2-mCh construct, under analogous illumination conditions, 
fails to be retained by the mitochondria once illumination is halted. Given the fact that cells 
harboring Cry2-mCh-BaxS184E suffer brisk apoptosis (1 h) relative to cells containing 
BaxS184E-Cry2-mCh (2 – 3 h), it is tempting to speculate that the Cry2-mCh-BaxS184E 
construct undergoes more efficient mitochondrial oligomerization and/or OMM insertion 
than its BaxS184E-Cry2-mCh counterpart.
We also assessed whether anticipated apoptotic events, downstream of Bax recruitment to 
the mitochondria, are triggered following illumination. Proteolytic conversion of the inactive 
caspase-3 zymogen to the active caspase-3 fragment (17 kDa) serves as a barometer of the 
cell’s commitment to the execution phase of apoptosis.[16] Since the 17 kDa fragment was 
assayed via western blot analysis (as opposed to microscopy), we once again resorted to 
bench-top illumination using the in-house built LED array. Transfected Cos7 cells were 
illuminated for 2 s, every 2 min, over the course of 1, 2, or 3 h. As anticipated, both BaxWT 
and BaxS184E, positioned at either the N- or the C-terminus (Bax-Cry2-mCh and Cry2-mCh-
Bax, respectively), mediate the light triggered formation of the 17 kDa caspase fragment 
(Supporting Fig. 10). By contrast, an increase in 17 kDa fragment formation was not 
observed with light alone or upon light-triggered migration of Cry2-mCh to the 
mitochondria. We also note that the BaxWT constructs induce a 50% higher caspase-3 
fragment background in the dark than the corresponding BaxS184E mutants. This undesired 
dark activity is a common problem with optogenetic proteins and highlights the importance 
of employing mutant constructs whose endogenous activities are biochemically 
compromised. The observed dark activity for the BaxWT construct may be due to the 
equilibrium between the cytosol and the mitochondria for the WT protein that exists even in 
the absence of an apoptotic insult.[14] Of the four Bax constructs, BaxS184E-Cry2-mCh is the 
most effective, producing a 3.5-fold increase in caspase-3 fragment generation upon 
illumination, while maintaining a modest caspase-3 fragment background in the dark 
(Supporting Fig. 10).
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To further assess whether the Bax constructs are acting in a manner consistent with Bax-
dependent apoptosis, we examined the mitochondrial release of Smac1, using a Smac11–60-
GFP fusion. Smac1 resides in the mitochondria intermembrane space, and is known to co-
disperse with cytochrome C during Bax-induced apoptosis.[17] As expected, we observed the 
light-triggered loss of Smac1 from mitochondria during Bax-induced cellular collapse (Fig. 
3, Supporting Movie 4). This release is not gradual, but occurs rapidly as cells transition 
from adherent to non-adherent, an observation consistent with the fact that specific critical 
apoptotic biochemical events can occur within minutes.[18]
Finally, we tested the effects of several inhibitors on cells containing the optogenetic Bax 
constructs. V5 (1) is a cell permeable peptide that inhibits the mitochondrial translocation of 
Bax (endogenous or overexpressed) by disrupting the interaction between Bax and Ku70.[19] 
At a concentration (200 µM) sufficient to block the cytosol-to-mitochondrial migration of 
overexpressed wild type Bax,[19] optogenetic Bax still induces rapid cell collapse 
(Supporting Movie 5/Supporting Table 1). V5’s ineffectiveness is expected since light-
induced migration of optogenetic Bax to the mitochondria occurs independently of the Ku70 
mechanism employed by its’ endogenous counterpart. We also tested a cocktail of 
cyclosporin A and aristolochic acid (5 µM CyA/50 µM ArA; 2), which disrupts the Ca2+ 
MPT, but not the Bax/Mg2+ MPT.[20] Once again, as anticipated, this cocktail fails to inhibit 
the light-mediated pro-apoptotic action of optogenetic Bax (Supporting Movie 5/Supporting 
Table 1). Finally, we examined the action of an inhibitor (3)[21] that blocks the mitochondrial 
apoptosis-induced channel (MAC), which is formed by Bax and is the conduit through 
which cytochrome C is released. We found that not only is the MAC channel inhibitor 
effective at blocking light-induced apoptosis (Supporting Movie 5/Supporting Table 1), but 
that the inhibitory action is also titratable over a 1 – 10 µM concentration range of inhibitor 
3 (Supporting Movie 6/Supporting Table 2).[21] These results are consistent with the 
reported near complete inhibition of mitochondrial permeability by 3 (10 µM)[21] and 
strongly suggests that optogenetic Bax forms a MAC analogous to that of the endogenous 
protein.
The therapeutic interest in Bax-mediated apoptosis encompasses a wide array of diseases, 
from cancer to neuropathologies. As a consequence, a variety of tools have been developed 
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to explore and/or perturb apoptotic pathways, including small molecule inhibitors and 
activators.[22] Light has been used, in conjunction with photosensitizers[23] or genetically 
expressed proteins[24], to induce reactive oxygen species and cell death. In addition, a 
variety of light-responsive small molecules have been described that trigger cell death via an 
array of miscellaneous mechanisms.[25] Optogenetics offers the ability to use light to initiate 
an action, with exquisite temporal, spatial and biochemical precision, which provides the 
ability to correlate an investigator-defined biochemical event with cellular behavior. With 
this in mind, there is intense interest in exploring the aberrant Bax-mediated activity 
associated with Alzheimer’s Disease (AD) and developing appropriate animals models that 
can be used to assess therapeutic efficacy.[26} Furthermore, the geographical course of AD, 
from the hippocampus out to the cortex, is a spatially well-defined phenomenon; one that 
optogenetics may prove to be uniquely capable of addressing.
In summary, we’ve developed an optogenetic design strategy that is based on the aberrant 
mitochondrial migration behavior of Bax mutants in response to pro-apoptotic insults. This 
strategy furnishes constructs that display minimal dark activity, an otherwise common 
problem associated with optogenetic engineering. Finally, we’ve identified two constructs 
that exhibit distinct properties: both Cry2-mCh-BaxS184E and BaxS184E-Cry2-mCh elicit 
light-mediated cell death, however the former also migrates to the mitochondria in response 
to conventional pro-apoptotic signals (exposure to STS) whereas the latter remains 
cytoplasmic under these conditions.
Supplementary Material
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Visualization of recruitment of Cry2-mCh to the mitochondria in MtLn3 cells via confocal 
microscopy. Cells are shown (a) prior to and (b) following 488 nm illumination. The 
localization construct (Tom20-Cib-GFP) is shown in (c). See Supporting Fig. 1 for results 
with HeLa and Cos7 cell lines.
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Visualization of Cry2-mCh-BaxS184E (a – c) and Cry2-mCh (d – f) light-triggered 
recruitment to mitochondria in HeLa cells and the attendant cell morphology. Cells are 
shown prior to illumination (a, d), 2 min (b, e), and 18 min after first light pulse (10 ms 
pulse every 2 min). Cry2-BaxS184E cells undergo rapid shrinkage (b) and eventual 
detachment (c; see middle cell), while Cry2-mCh cells maintain an adherent morphology 
throughout the light course.
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Visualization of Smac1-GFP release from mitochondria of Cry2-mCh-BaxS184E/Tom20-Cib/
Smac1-GFP transfected HeLa cells. (a) Initial localization of Smac1 is mitochondrial. A 10 
ms pulse was then applied every 2 min. At the (b) 12 and (c) 14 min time points Smac1 
localization is distinctly less mitochondrial during cellular collapse.
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Design of a genetically encoded optogenetic Bax. A Bax mutant (black) is appended to the 
light-responsive Cry2 (light blue). In the absence of light, the Bax construct remains 
cytoplasmic. Upon illumination at 488 nm, Cry2 associates with mitochondria-bound Cib 
(blue), furnishing a high effective Bax concentration, promoting Bax oligomerization, 
mitochondrial pore transition, Smac1 release, caspase 3 fragment formation, and eventual 
cell death.
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Table 1
Optogenetic Bax constructs and their subcellular location.
Construct Dark Dark + STS[a] Mitochondrial
Half-Life[b]
Cry2-mCh-BaxWT Mitochondrial + Cytoplasmic Mitochondrial 200 ± 10 s
Cry2-mCh-BaxS184E Cytoplasmic Mitochondrial 210 ± 10 s
Cry2-mCh-BaxS184V Mitochondrial Mitochondrial N.D. [c]
BaxWT-Cry2-mCh Cytoplasmic Cytoplasmic 130 ± 10 s
BaxS184E-Cry2-mCh Cytoplasmic Cytoplasmic 130 ± 10 s




Mitochondrial residence time following a single 100 ms 488 nm light pulse,
[c]
N.D. = Not determined.
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